Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Recursion Pharmaceuticals Inc (RXRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: RXRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.14
1 Year Target Price $7.14
| 1 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.89% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.34B USD | Price to earnings Ratio - | 1Y Target Price 7.14 |
Price to earnings Ratio - | 1Y Target Price 7.14 | ||
Volume (30-day avg) 8 | Beta 0.83 | 52 Weeks Range 3.79 - 12.36 | Updated Date 07/17/2025 |
52 Weeks Range 3.79 - 12.36 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1297.85% |
Management Effectiveness
Return on Assets (TTM) -38.51% | Return on Equity (TTM) -86.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1855729863 | Price to Sales(TTM) 39.09 |
Enterprise Value 1855729863 | Price to Sales(TTM) 39.09 | ||
Enterprise Value to Revenue 31.46 | Enterprise Value to EBITDA -5.31 | Shares Outstanding 426739008 | Shares Floating 388515723 |
Shares Outstanding 426739008 | Shares Floating 388515723 | ||
Percent Insiders 5.1 | Percent Institutions 74.16 |
Upturn AI SWOT
Recursion Pharmaceuticals Inc
Company Overview
History and Background
Recursion Pharmaceuticals Inc. was founded in 2013. It leverages artificial intelligence (AI) and high-throughput screening to discover and develop novel therapeutics. A significant milestone was its partnership with Bayer in 2020. It has evolved from a drug discovery platform to a clinical-stage biotechnology company.
Core Business Areas
- Drug Discovery Platform: Recursion operates a technology platform that combines biology, chemistry, automation, and AI to identify potential drug candidates for various diseases. This involves screening millions of potential therapies against cellular models.
- Drug Development: Recursion advances identified drug candidates through preclinical and clinical development. Their pipeline includes programs in various therapeutic areas, including oncology, neuroscience, and rare diseases.
- Software Licensing and Partnerships: Recursion licenses their software platform and datasets to other pharmaceutical companies and research institutions, generating revenue through collaborations and partnerships.
Leadership and Structure
The leadership team includes Chris Gibson (CEO), and key executives overseeing research, development, and finance. The organizational structure is based on functional departments, with dedicated teams for drug discovery, clinical development, and technology.
Top Products and Market Share
Key Offerings
- REC-994: A clinical-stage drug candidate targeting cerebral cavernous malformation (CCM). Recursion is currently undergoing clinical trials. Competitors include companies developing therapies for vascular abnormalities but specific market share data for CCM is not easily available. Revenue from product is currently 0 but has a good projected revenue for the coming years. Competitors are not specifically targeted CCM but work on other vascular problems.
- Phenix Platform: Recursion's proprietary drug discovery platform utilizing high-content cellular imaging and AI. This is a technology offering, not a drug, and does not have a direct market share in the traditional sense. Instead, its competitive advantage lies in its speed and efficiency in identifying drug candidates. Competitors include companies offering AI-powered drug discovery services, such as Schru00f6dinger (SDGR) and Exscientia (EXAI), but Recursion's specific niche is its focus on phenotypic screening.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing a growing adoption of AI and machine learning for drug discovery, development, and clinical trials. The trend towards personalized medicine is also driving demand for more targeted therapies.
Positioning
Recursion Pharmaceuticals Inc is positioned as a leader in AI-powered drug discovery, focusing on phenotypic screening and high-content cellular imaging. Its competitive advantage lies in its proprietary technology platform and extensive datasets.
Total Addressable Market (TAM)
The TAM for AI in drug discovery is estimated to be in the tens of billions of dollars, with projections varying depending on the scope and inclusion criteria. Recursion is positioned to capture a portion of this market through its drug development pipeline and software licensing agreements.
Upturn SWOT Analysis
Strengths
- Proprietary AI-powered drug discovery platform
- Extensive datasets and high-content cellular imaging capabilities
- Partnerships with major pharmaceutical companies
- Clinical-stage drug candidates in multiple therapeutic areas
- Strong intellectual property portfolio
Weaknesses
- High research and development expenses
- Dependence on successful clinical trial outcomes
- Competition from other AI-powered drug discovery companies
- Limited revenue generation to date
Opportunities
- Expansion of drug development pipeline
- Further partnerships with pharmaceutical companies
- Application of AI platform to new therapeutic areas
- Increased adoption of AI in drug discovery
- Licensing of AI platforms to other companies
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Economic downturn affecting investment in biotechnology
- Technological obsolescence
Competitors and Market Share
Key Competitors
- EXAI
- SDGR
- CRSP
- LLY
Competitive Landscape
Recursion has a competitive advantage in phenotypic screening and high-content cellular imaging. Compared to the other competitors in the market their AI capabilities may not be as mature.
Growth Trajectory and Initiatives
Historical Growth: The company has grown through strategic collaborations and expanding its drug discovery pipeline. Revenue growth has been present but not in a straight line, with peaks and valleys.
Future Projections: Analyst estimates suggest continued growth in revenue and pipeline development, driven by AI-powered drug discovery. The actual growth rates and numbers are not provided, however.
Recent Initiatives: Recent initiatives include partnerships with pharmaceutical companies, expansion of the drug development pipeline, and advancements in AI platform capabilities.
Summary
Recursion Pharmaceuticals is a clinical-stage biotechnology company using AI to improve drug discovery and development. They are growing in revenue but are not profitable at this time and have high R&D spend. A risk for the company is failure of clinical trials, and also the fact that it does not have many products on the market. Their main strength is the AI platform for drug discovery.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Financial News Outlets
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Recursion Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2021-04-16 | Co-Founder, CEO & Director Dr. Christopher C. Gibson Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 800 | Website https://www.recursion.com |
Full time employees 800 | Website https://www.recursion.com | ||
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.